PET-CT Surveillance Cost-Effective for Locally Advanced Head and Neck Squamous Cell Cancer

PET-CT Surveillance Cost-Effective for Locally Advanced Head and Neck Squamous Cell Cancer
PET-CT Surveillance Cost-Effective for Locally Advanced Head and Neck Squamous Cell Cancer

CHICAGO–PET-CT guided active surveillance in patients with locally advanced head and neck squamous cell cancer (HSNCC) compared with node dissection is cost-effective over a short time horizon, data presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting have shown.

For the analysis, researchers analyzed the cost-effectiveness of the PET-NECK study that evaluated 564 patients with locally advanced nodal metastases of HNSCC receiving chemoradiotherapy and eligible for node dissection. Patients in that study were randomly assigned them 1:1 to undergo planned node dissection before or after chemoradiotherapy (control) or chemoradiotherapy followed 10 to 12 weeks by FDG-PET-CT with node dissection only if PET-CT demonstrated incomplete or equivocal response of nodal disease.

Result of the cost analysis showed that PET-CT guided surveillance produced an average per-person cost savings of £1,415 (95% CI: -607, -2,218) and a health gain of 0.07 QALYs (95% CI: -0.04, 0.19) compared with planned node dissection.

“At a £20,000 per QALY threshold, PET-CT guided management is associated with a 99% probability of being cost saving and a 91% probability of being more cost-effective than planned node dissection,” said Alison Smith, Research Fellow at the Leeds Institute of Health Sciences in the United Kingdom.

However, in a lifetime cost-effectiveness model, the study showed that PET-CT guided management is associated with only a 50% probability of being cost-effective compared with planned node dissection.

The findings suggest that PET-CT surveillance is cost-effective over the trial period of about 3 years.

“The results of the within-trial cost-effectiveness analysis clearly support the findings of the trial effectiveness analysis,” Smith concluded. “The long-term impact of this strategy is uncertain. Further exploration of key model parameters and assumptions, especially regarding long-term recurrence, is required in order to determine the necessity for further research.”

Reference

1. Smith AF, Hall P, Hulme C, et al. Is PET-CT guided management for patients with locally advanced head and neck squamous cell cancer (HNSCC) cost-effective? Results from a UK non-inferiority phase III randomized trial.

J Clin Oncol. 2015;33:(suppl; abstr 6010).
Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs